Categories: CancerNews

Theriva Biologics to Participate in Upcoming Investor Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will participate in the following upcoming investor conferences in December.

Detail on the conferences can be found below.

Alliance Global Partners Virtual Series
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, December 7, 2022
Time: 11:00 AM ET
Webcast: Click here

Sidoti Virtual Conference
Format: Corporate update and one-on-one investor meetings
Date: Thursday, December 8, 2022
Time: 9:15 AM ET
Webcast: Click here

The webcast of the presentation will be accessible in the “Investors” section of the company’s website, https://www.therivabio.com, under “Events.”

About Theriva Biologics, Inc.

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.

For further information, please contact:

Investor Relations:

Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

Staff

Recent Posts

NextPlat Corp Receives Nasdaq Notification Regarding Minimum Bid Requirements

COCONUT GROVE, Fla., April 28, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or…

2 hours ago

TV STARS WALK THE WALK FROM COAST TO COAST AT PANCAN PURPLESTRIDE, THE ULTIMATE WALK TO END PANCREATIC CANCER

Reality Star Joan Vassos, "Star Trek" Team, Days of our Lives' Martha Madison & Cast Members…

2 hours ago

AI, Compliance, and Modernization Top Priorities for Healthcare IT Leaders in 2025, According to Info-Tech Research Group’s New Report

A new report from global research and advisory firm Info-Tech Research Group highlights the top…

2 hours ago

Hixny’s Snapshot Application Now Available to All Providers in New York

In a new SHIN-NY collaboration, Hixny has made it easy for providers across the stateto screen patients for HRSN and query the state's controlled substance database. ALBANY, N.Y., April 28, 2025 /PRNewswire/ -- Hixny,…

2 hours ago

CliniComp Launches Enterprise PACS, Fully Integrated into their New Era EHR with Intrinsic AI™

PACS fuels faster, more precise diagnosis and patient triaging for busy healthcare providers to assist…

2 hours ago